Gene-Disorder Association · Article
Gene
MDM2MDM2 Proto-Oncogene
×
First reported
1998
Supporting publications
32
Manually curatedApproved treatment annotated
Association Review
In brief
The association between MDM2 (MDM2 Proto-Oncogene) and Lung Cancer is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
13
Compounds
3
Trials
320of 4,223 via MDM2 compounds
Publications
32
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
31 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features
3 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics
3 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
4,223 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
32 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources
17 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access